Literature DB >> 30308494

Tip60 Suppresses Cholangiocarcinoma Proliferation and Metastasis via PI3k-AKT.

Yaodong Zhang, Guwei Ji, Sheng Han, Zicheng Shao, Zefa Lu, Liqun Huo, Jiawei Zhang, Renjie Yang, Qinchao Feng, Hao Shen, Hongwei Wang, Xiangcheng Li.   

Abstract

BACKGROUND/AIMS: Aberrant expression of Tip60 is associated with progression in many cancers. However, the role of Tip60 in cancer progression remains contradictory. The aim of this study was to investigate the clinical significance, biological functions and underlying mechanisms of Tip60 deregulation in cholangiocarcinoma (CCA) for the first time.
METHODS: Quantitative real-time PCR (QRT-PCR), western blotting and immunohistochemistry staining (IHC) were carried out to measure Tip60 expression in CCA tissues and cell lines. Kaplan-Meier analysis and the log-rank test were used for survival analysis. In vitro, cell proliferation was evaluated by flow cytometry and CCK-8, colony formation, and EDU assays. Migration/ invasion was evaluated by trans-well assays. Phosphokinase array was used to confirm the dominant signal regulated by Tip60. Tumor growth and metastasis were demonstrated in vivo using a mouse model.
RESULTS: Tip60 was notably downregulated in CCA tissues, which was associated with greater tumor size, venous invasion, and TNM stage. Down-regulation of Tip60 was associated with tumor progression and poorer survival in CCA patients. In vitro and in vivo studies demonstrated that Tip60 suppressed growth and metastasis throughout the progression of CCA. We further identified the PI3K/AKT pathway as a dominant signal of Tip60 and suggested that Tip60 regulated CCA cell proliferation and metastasis via PT3K-AKT pathway. Pearson analysis revealed that PTEN was positively correlated with the Tip60 level in CCA tissues.
CONCLUSION: Tip60, as a tumor suppressor in CCA via the PI3K/AKT pathway, might be a promising therapeutic target or prognostic marker for CCA.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Cholangiocarcinoma; Metastasis; Proliferation; Tip60

Mesh:

Substances:

Year:  2018        PMID: 30308494     DOI: 10.1159/000494183

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  6 in total

1.  Early growth response 1 transcription factor is essential for the pathogenic properties of human endometriotic epithelial cells.

Authors:  Vineet K Maurya; Maria M Szwarc; Rodrigo Fernandez-Valdivia; David M Lonard; Song Yong; Niraj Joshi; Asgerally T Fazleabas; John P Lydon
Journal:  Reproduction       Date:  2022-06-27       Impact factor: 3.923

2.  LncRNA NRON down-regulates lncRNA snaR and inhibits cancer cell proliferation in TNBC.

Authors:  Limin Niu; Qingxia Fan; Min Yan; Liuxing Wang
Journal:  Biosci Rep       Date:  2019-05-14       Impact factor: 3.840

Review 3.  Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy.

Authors:  Donglu Wu; Ye Qiu; Yunshuang Jiao; Zhidong Qiu; Da Liu
Journal:  Front Oncol       Date:  2020-11-11       Impact factor: 6.244

4.  GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration.

Authors:  Jun Zhou; Wanpin Nie; Jiajia Yuan; Zeyu Zhang; Liangliang Mi; Changfa Wang; Ranglang Huang
Journal:  Oncol Rep       Date:  2021-04-13       Impact factor: 3.906

5.  YY1 activates EMI2 and promotes the progression of cholangiocarcinoma through the PI3K/Akt signaling axis.

Authors:  Shuai Zhou; Kang Lin Qu; Jin Ang Li; Shi Lei Chen; Yi Gang Zhang; Chao Zhu; Hao Jin; Yong Wang; Qing Pang; Hui Chun Liu
Journal:  Cancer Cell Int       Date:  2021-12-21       Impact factor: 5.722

6.  Downregulation of MCM8 expression restrains the malignant progression of cholangiocarcinoma.

Authors:  Jingcheng Hao; Haimin Deng; Yuan Yang; Lidan Chen; Qiang Wu; Pei Yao; Junen Li; Bowen Li; Xueli Jin; Haiqing Wang; Huaxin Duan
Journal:  Oncol Rep       Date:  2021-09-15       Impact factor: 3.906

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.